drugset / Trial / NCT05165550

Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects

NCT05165550

Phase 1 Completed 24 enrolled Viriom
RandomizedSequentialTriple-blindTreatment

Summary

To assess the safety and tolerability of Elsulfavirine following administration of single oral ascending doses in HIV-negative, healthy subjects.

Timeline

Start
2022-04-12
Primary completion
2022-07-13
Completion
2022-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Elsulfavirine Small molecule 20 mg Oral
Subject Elsulfavirine Small molecule 40 mg Oral
Subject Elsulfavirine Small molecule 80 mg Oral